Miriam Pollack

About Miriam Pollack

Miriam specialised in neuroscience as an undergraduate but traded in lab work for a post graduate degree in science communication. She is now working on a Masters in Human Nutrition.

Metabolic Syndrome: Understanding the Risk Factors

The risk factors associated with metabolic syndrome are dyslipidemia, hypertension, central obesity and hyperglycemia.1 But what exactly is each of these conditions? How are they defined? And what is their role in metabolic syndrome?
Central Obesity
Central obesity has an ethnic and country specific definition, but it generally refers to increased waist circumference due to fat deposition […]

By |August 3rd, 2015|Metabolic Disorder|0 Comments

Tissue-Based Diagnostic Tests for HER-2 in Breast Cancer

There are currently three tissue-based diagnostics available to test for HER-2 positive breast cancer:

Immunohistochemistry
Inform Dual In Situ Hybridization
Fluorescence In Situ Hybridization

Pathologists use HER-2 tissue tests to detect a protein called HER-2 (“human epidermal growth factor receptor 2”) that is found in certain types of cancer cells.   Alternatively, some tests are designed to detect the HER-2 […]

By |July 27th, 2015|Breast Cancer|0 Comments

What is Metabolic Syndrome?

Metabolic syndrome is not, in and of itself, a disease. It is a term that was initially coined by the World Health Organization (WHO) in the late 1990s to identify people at a greater risk of developing cardiovascular disease (CVD).1  In essence, metabolic syndrome refers to a cluster of diseases that confer a cumulative risk […]

By |July 17th, 2015|Metabolic Disorder|0 Comments

The Importance of HER-2 Testing During Treatment for Breast Cancer

The more HER-2 genes a breast cancer cell has, the more HER-2 protein that cell will produce and the faster the cancer will grow. If a breast cancer patient is diagnosed with a positive HER-2 status, they typically will receive a targeted treatment such as Herceptin or Tykerb.1

However, even after treatment begins, HER-2 status remains […]

By |July 13th, 2015|Breast Cancer|0 Comments